Literature DB >> 33452981

Clinical and Experimental Evaluation of Diagnostic Significance of Alpha-Fetoprotein and Osteopontin at the Early Stage of Hepatocellular Cancer.

Z Macek-Jilkova1,2, S I Malov3, K Kurma2, C Charrat2, T Decaens1,2, N P Peretolchina4, P N Marche2, I V Malov4, N D Yushchuk5.   

Abstract

We evaluated the possibility of using an experimental model of hepatocellular carcinoma to study oncomarkers of primary liver cancer and compared the diagnostic efficacy of alpha-fetoprotein and osteopontin in the experiment and in clinical practice. Experimental studies were performed on a model of hepatocellular carcinoma induced by administration of diethyl nitrosamine to Fisher-344 rats. In addition, the levels of α-fetoprotein and osteopontin were determined in 35 patients with hepatocellular carcinoma detected at stages I-II according to TNM classification. The proposed model of liver cancer in rats reflects the sequence of stages characteristic of hepatocellular carcinoma in humans: liver fibrosis-cirrhosis-cancer. This model is applicable for the study of tumor markers at the early stage of tumor development. Osteopontin was found to have a more powerful diagnostic potential then alpha-fetoprotein.

Entities:  

Keywords:  alpha-fetoprotein; diethylnitrosamine; hepatocellular carcinoma; oncomarkers; osteopontin

Year:  2021        PMID: 33452981     DOI: 10.1007/s10517-021-05063-0

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  1 in total

1.  Measuring levels of osteopontin as potential biomarker for hepatocellular carcinoma in Syrian patients.

Authors:  Sara Al-Zoubi; Ahmad Wassouf; Almoutassem Billah Zetoune
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2017
  1 in total
  1 in total

Review 1.  Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment.

Authors:  Mariam Mroweh; Gaël Roth; Thomas Decaens; Patrice N Marche; Hervé Lerat; Zuzana Macek Jílková
Journal:  Int J Mol Sci       Date:  2021-02-11       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.